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ABSTRACT
Objective Proton pump inhibitors (PPIs) are drugs
used to suppress gastric acid production and treat GI
disorders such as peptic ulcers and gastro-oesophageal
reﬂux. They have been considered low risk, have been
widely adopted, and are often over-prescribed. Recent
studies have identiﬁed an increased risk of enteric and
other infections with their use. Small studies have
identiﬁed possible associations between PPI use and GI
microbiota, but this has yet to be carried out on a large
population-based cohort.
Design We investigated the association between PPI
usage and the gut microbiome using 16S ribosomal RNA
ampliﬁcation from faecal samples of 1827 healthy twins,
replicating results within unpublished data from an
interventional study.
Results We identiﬁed a signiﬁcantly lower abundance
in gut commensals and lower microbial diversity in PPI
users, with an associated signiﬁcant increase in the
abundance of oral and upper GI tract commensals. In
particular, signiﬁcant increases were observed in
Streptococcaceae. These associations were replicated in
an independent interventional study and in a paired
analysis between 70 monozygotic twin pairs who were
discordant for PPI use. We propose that the observed
changes result from the removal of the low pH barrier
between upper GI tract bacteria and the lower gut.
Conclusions Our ﬁndings describe a signiﬁcant impact
of PPIs on the gut microbiome and should caution over-
use of PPIs, and warrant further investigation into the
mechanisms and their clinical consequences.
INTRODUCTION
Proton pump inhibitors (PPIs) are used to increase
gastric pH by suppressing acid production. They
are pro-drugs, only becoming functional in the
acidic environment of the stomach. Here, activated
PPIs inhibit hydrogen–potassium pumps (H+/K+
ATPases), transmembrane proteins responsible for
releasing hydrochloric acid into the lumen of the
stomach. PPIs inhibit H+/K+ ATPases by binding
covalently to the transmembrane domain, with
return of acid production dependent on the turn-
over of new H+/K+ ATPases once PPIs have left
the system.1
PPIs are frequently used to treat GI tract disor-
ders such as bleeding peptic ulcers, erosive esopha-
gitis, and gastroesophageal reﬂux.2–4 They are also
used prophylactically to prevent stress ulcers and to
reduce GI toxicity associated with certain medica-
tions, including non-steroidal anti-inﬂammatory
drugs, aspirin, and steroids, sometimes despite a
paucity of evidence.5–8 PPIs are one of the most
proﬁtable classes of drugs in the world9; however,
the high cost to healthcare systems has led to inves-
tigations into possible over-utilisation. These show
that over 70% of PPI prescriptions may be inappro-
priate,10–12 with the majority of over-utilisation
Signiﬁcance of this study
What is already known on this subject?
▸ Proton pump inhibitors (PPIs) are widely, and
often over, used but recently have been
associated with a number of side effects,
including an increased risk of Clostridium
difﬁcile infection.
▸ The increased risk of infection may be
mediated by alterations to the gut microbiota,
as observed with antibiotics.
▸ Previous studies have demonstrated
associations between PPI use and the gut
microbiota, but have been limited in size.
What are the new ﬁndings?
▸ In a large healthy twin cohort, we identify
signiﬁcant associations between the
composition of the gut microbiota and PPI use.
▸ The most striking association is an increase in
Lactobacillales, particularly Streptococcaceae, in
PPI users.
▸ The strongest associations replicated in a small
interventional dataset indicating causality.
▸ Finally, we show that bacterial families
increasing with PPI use are more likely to be
pharyngeal, not gut, commensals.
How might it impact on clinical practice in
the foreseeable future?
▸ The observed alterations to the gut microbiota
with PPI use may be responsible for the
observed increases in infection risk, and
therefore provide targets for research to
mitigate these risks.
▸ The potential consequences of these changes
are motivation for caution against unnecessary
provision of PPIs.
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stemming from unnecessary stress ulcer prophylaxis in patients
who do not meet the evidence-based criteria, and a lack of
re-assessment of PPI use in the community.12
The use of PPIs has generally been considered safe, with low
reported incidences of serious adverse outcomes.13–15 However,
recently a number of side effects have been identiﬁed, including
nutritional deﬁciencies, increased risk of bone fracture, and risks
of enteric and other infections16–19; notably, increased risks of
community acquired pneumonia and Clostridium difﬁcile infec-
tion where PPIs may carry a high risk equivalent to that of oral
antibiotics.20 21
The term microbiome refers to the ecology and functionality
of the microbial population within an environment. Nearly every
site of the human body has a distinct microbiome with bacterial
composition determined by environmental and inter-microbial
inﬂuences.22 23 Using ampliﬁcation and sequencing of the vari-
able regions of the 16S ribosomal subunit it is possible to proﬁle
the taxonomic composition of the microbiome of a given
sample.23 Application of this technique has shown changes to gut
microbiota in a range of conditions, from IBD to obesity and
frailty.24–26 Thus, factors affecting the microbiome have the
potential to drive important secondary effects on health. For
example, alterations to microbial communities caused by oral
antibiotics may underlie their association with increased C difﬁ-
cile infection,27 and the same could be true for PPIs.
Previous small-scale case–control studies indicate that PPI use
can inﬂuence the microbiome, but have been limited by focusing
on younger individuals or patients presenting a GI disorder,
with some conﬂicting results.28–32
Here we investigate the association between PPI usage and the
gut microbiota in the largest study published to date, using 16S
rRNA proﬁling of faecal samples collected from over 1800
healthy elderly twin volunteers, allowing adjustment for environ-
mental and heritable factors inﬂuencing both PPI use and the
microbiome. We identiﬁed signiﬁcant alterations to the diversity
and composition of the gut microbiota in PPI users, a number of
which were replicated in an intervention study. We also identiﬁed
a potential mechanism by which PPIs could induce such changes.
METHODS
Microbiota composition analysis
One thousand and eighty-one faecal samples from the TwinsUK
cohort had been sequenced as part of a previous study; a
further ∼1000 twin samples were collected and processed under
the same protocol producing reads with an average length of
253nt after barcode removal.33 Previously generated sequencing
was combined with new data and quality ﬁltering and ecological
analysis performed using QIIME.34 Sequences were collapsed to
operational taxonomic units (OTUs) using open reference clus-
tering with Greengenes v13_8 at 97% sequence similarity. The
OTU table was then sub-set to samples from twins with PPI
usage data for use in subsequent analyses.
Medication and GI indication data
PPI use was self-reported at multiple time points up to 10 years
before and including microbiome assessment. Use was scored as
positive if an individual had reported usage at any time, even if
there was a more recent negative report. This method was
chosen, as PPI use is often intermittent, the longevity of any PPI
mediated microbiome effects are unknown, and most misclassiﬁ-
cations would be non-users appearing as users, which would act
to reduce the strength of any observed associations. Positive PPI
use was recorded a median of 3 years before microbiota assess-
ment (IQR 0.2–4.7 years).
GI indications were scored similarly based on self-reported or
professionally diagnosed indications for PPI prescription. As for
PPI use, multiple time points were available and individuals
were considered positive if any indication had ever been
reported. Positive GI indications were a median of 1.5 years
from faecal sampling (IQR 0–3.8 years).
Self-reported antibiotic use within the previous month was
recorded at the time of sample collection for the majority of
individuals, with drug details provided where applicable. Binary
scores created from these data were corrected to reﬂect reported
treatments, removing individuals where the reported drug was
not an antibiotic.
Cohort and covariate data collection
Within TwinsUK 1827 individuals had both PPI data and faecal
samples. The average age was 62 years (range 19–88 years) and
90% were female. The gender and age distribution resulted
from historical study recruitment within the cohort.35 Physical
measurements such as height and weight were measured at the
time of sample collection.
Habitual dietary patterns were represented by the ﬁrst ﬁve
principle components (PCs) of food frequency questionnaires
(FFQs) collected before sample collection. These have previously
been shown to account for the majority of habitual diet variance
and correspond to dietary types (given the names of fruit and
vegetable rich, high alcohol, traditional English dieting and low
meat diets, respectively).36 Frailty was quantiﬁed as a Frailty
Index (FI) using the proportion of 39 binary health deﬁcits that
each individual displayed (see online supplementary table S1)
from the Healthy Ageing Twin Study collected in 2007–
2010.35 37 Covariate distributions were analysed using two-tailed
Wilcoxon rank sum tests to compare the distributions of PPI
users and non-users, with a signiﬁcance threshold of p<0.05.
α Diversity
The 1827 samples had a mean OTU count of 82 130
(s=40 506, range 10 460–380 500). The OTU table was rareﬁed
to a depth of 10 000 sequences and used to generate Shannon,
Chao1 and phylogenetic diversity indices, as well as observed
OTU counts. One-tailed Wilcoxon rank sum tests were per-
formed to test for lower diversity in PPI users versus
non-users,32 taking a signiﬁcance threshold of p<0.05 on the
full set of 1827 individuals.
Mixed effects models were created using the lme4 package in
R,38 with α diversity metrics as the response variable to assess the
ability of PPI status to predict diversity. Technical covariates
included sequencing run and depth of sample sequencing. Other
covariates included family, twin structure (a variable of unique
values the same for monozygotic (MZ) but different for dizygotic
(DZ) twins), diet (the ﬁrst ﬁve PCs from FFQs), age, body mass
index (BMI), FI (root normalised), and GI indication status. The
Anova function was used to compare the ability of models with
and without PPI status to predict each α diversity metric, using
the subset of 1200 individuals with complete covariate data.
OTU and taxonomic associations
Mixed effects models were again used to identify associations
between PPI use and OTU and taxa abundances on 1200 indivi-
duals having complete covariate data. OTUs present in <25%
of individuals were discarded and the remaining counts con-
verted to log transformed relative abundances (with the addition
of 10−6 for zero counts). OTU abundances were used as
response variables with covariates as above also including the
Shannon index, to reduce associations with OTU markers of α
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diversity. The ability of models including and not including PPI
status as a covariate to predict abundance of each OTU was
quantiﬁed using the Anova function in R. p Values were FDR
(false discovery rate) corrected using the ‘qvalue’ package with a
signiﬁcance threshold of 5%.39 OTU counts were collapsed by
shared taxonomy at all taxonomic levels. Modelling was carried
out for each level individually in the same manner as for OTUs.
These analyses were repeated within the subset of individuals
who had not used antibiotics.
Interventional study replication
To further assess the possible causal link between exposure to PPIs
and the observed taxonomic changes in TwinsUK, we re-analysed
data from a previously published crossover study. Methods for this
study have been described.31 In brief, 12 healthy adult volunteers
not exposed to antibiotics within the previous 12 months each
took 40 mg of omeprazole twice daily for 4–8 weeks, and donated
stool samples before and after the PPI course. Bacterial DNA was
extracted from all samples and the V4 region of the 16S rRNA
gene was ampliﬁed using a primer set identical to that used in the
TwinsUK study. As for the TwinsUK cohort, the Greengenes data-
base was used for ﬁnal taxonomic assignments. To best compare
data, we assessed the taxonomic changes within the samples from
immediately before and immediately after 4 weeks of omeprazole.
We analysed taxa that were signiﬁcantly associated with PPI in
TwinsUK and present in the majority of individual specimens
(>50%) in the intervention study. We assessed the magnitude and
directions of within-individual changes using rank-sum tests (when
the distribution of data was not normal) or paired t tests.
Taxonomies assigned as ‘Other’ against the Greengenes reference
were not included as they were not comparable between sets.
RESULTS
PPI use in the TwinsUK cohort
Intermittent data on self-reported PPI usage and GI health over
a ∼10 year time span was available for 1827 individuals, com-
prising 374 DZ twin pairs, 410 MZ twin pairs and 259 single-
tons; 90% were female, with an average age of 62 years. Within
this set, 892 (49%) had reported some form of GI indication
for PPIs, 229 (12%) had been prescribed PPIs at some point
(only 24 having used PPIs without any GI indication), and 704
(39%) had reported neither PPI prescription nor GI indication.
PPI use is associated with age, BMI, frailty, and diet
A number of covariates were selected. These included: age, diet
as quantiﬁed using the ﬁrst ﬁve PCs from FFQs, BMI, and
frailty. The association of these with PPI use was assessed in the
subset of individuals with complete covariate data (n=1200,
175 having use PPIs) (ﬁgure 1). PPI users were signiﬁcantly
older (p<10−6), frailer (p<10−15), and had higher BMI
(p=0.002). They were also found to be signiﬁcantly lower
scoring on FFQ PC2 (p=0.0003), a dietary component related
to high alcohol intake.35
Signiﬁcantly lower diversity in the gut microbiome of PPI
users
There was signiﬁcantly lower (p<0.05) diversity in the gut
microbiota of PPI users compared to those not using PPIs with
all diversity indices (ﬁgure 2). There was no signiﬁcant differ-
ence, with any diversity metric, between the individuals with GI
indications compared to those without.
The observed negative association between PPI use and α
diversity did not withstand adjustment for family and twin
structure, BMI, age, frailty and GI indication, in the 1200 indi-
viduals with complete data (see online supplementary table S2).
PPI use is associated with speciﬁc taxonomic abundances
Modelling of OTU abundances against PPI use identiﬁed 22
OTUs with signiﬁcantly lower abundance in PPI users; all were
assigned to the phylum Firmicutes. There were 32 OTUs posi-
tively associated with PPI use, 20 from the order Bacteroidales
and seven assigned to the Streptococcus genus. The strongest
association was with a Biﬁdobacterium OTU (q<10−4, β=0.45),
followed by a Streptococcus assigned OTU (q<10−4, β=0.44)
(see online supplementary table S3).
To identify speciﬁc taxonomic relationships, modelling was
repeated against OTU abundances collapsed by shared taxo-
nomic assignment at various depths of classiﬁcation (see online
supplementary table S4). A summary of signiﬁcant associations
is shown in ﬁgure 3.
Seven collapsed species were negatively associated with PPI
use and were all assigned to Erysipelotrichales or Clostridiales
(except from one Cyanobacteria). At the level of genera, nine
were found to be negatively associated with PPI use, which were
largely Firmicutes, with members of the family
Erysipelotrichaceae being the most signiﬁcantly decreased. Five
families were negatively associated with PPI use, most strongly,
Lachnospiraceae (q=0.004, β=−0.35) and Ruminococcaceae
(q<0.0007, β=−0.26).
There were 24 species positively associated with PPI use. These
belonged to the phyla Actinobacteria, Bacteroidetes, Firmicutes
(particularly Lactobacillaceae and Clostridiales) and Proteobacteria.
The largest increases observed with PPI use were the species Rothia
mucilaginosa (q<10−6, β=0.51) and Streptococcus anginosus
(q<10−6, β=0.48). We observed 24 genera that were positively
associated with PPI use. The most signiﬁcantly increased were
Rothia (q<10−5, β=0.45) and Streptococcus (q<10−6, β=0.47).
Ten families were signiﬁcantly positively associated with PPI use,
the most signiﬁcant being Streptococcaceae (q<10−6, β=0.46) and
Micrococcaceae (q<10−5, β=0.46).
Taxonomic associations with PPI use are independent of
antibiotic use
Self-reported oral antibiotic usage data were available for
1 month before faecal sample collection for 1039 of the 1827
individuals. Antibiotic use was signiﬁcantly associated with PPI
use within this set (χ2(1, N=1309)=8.88, p<0.002), where
16% of PPI users had used antibiotics compared to only 8% of
individuals who had not used PPIs. To ensure this enrichment
was not inﬂuencing the observed associations, modelling ana-
lyses were repeated within a subset of 705 individuals that had
reported no antibiotic use and had complete covariate data (see
online supplementary table S5).
At all levels of analysis, from OTU to phylum, results
reﬂected those of the wider set. The number of signiﬁcant asso-
ciations was reduced because of the smaller sample size, but the
majority of associations were retained, particularly the strongest
positive associations with Streptococcaceae and other
Lactobacillales, and the negative associations observed with the
class Clostridia. These results show that the observed micro-
biome associations with PPI use are independent of increased
antibiotic utilisation.
Signiﬁcant associations between discordant twin pairs
The inﬂuence of PPIs on the microbiota of 70 MZ twins discord-
ant for PPI use was investigated to control for shared environ-
mental and genetic effects (see online supplementary methods).
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No signiﬁcant differences in the abundances of any OTU,
species or genera were observed between discordant MZs. The
Streptococcaceae family had a signiﬁcantly higher abundance in
PPI users within discordant twins (q=0.04, ×2.9 higher), as did
its parent order Lactobacillales (q=0.02, ×2.6 higher) (ﬁgure 4).
At higher taxonomic levels, signiﬁcant changes were observed
between twins for the classes Actinobacteria (q=0.03, ×1.3
higher in PPI users), Bacilli (q=0.03, ×1.9 higher), and
4C0D-2 (q=0.03, ×0.3 lower), and the phyla Actinobacteria
(q=0.04, ×1.1 higher), Cyanobacteria (q=0.04, ×0.33 lower),
and Verrucomicrobia (q=0.04, ×0.4 lower).
PPI microbiota associations replicate in an interventional
study
From the 96 collapsed taxonomies signiﬁcant in the TwinsUK
set, 63 were found in at least 50% of the interventional set and
considered for replication (see online supplementary table S4).
Within these, seven were signiﬁcantly associated with PPI use in
the intervention, all increasing in abundance after 4 weeks of
PPI use. These were unassigned species belonging to the genera
Streptococcus and Granulicatella, the Granulicatella genus, and
the families Carnobacteriaceae, Streptococcaceae,
Burkholderiaceae, and Corynebacteriaceae. All belonged to the
order Lactobacillales except Corynebacteriaceae and
Burkholderiaceae, which are from the orders Actinomycetales
and Burkholderiales. Within this size-limited intervention the
strongest taxa associations, particularly Lactobacilli, appear to
be driven by PPI use.
PPI use associated with a higher abundance of pharyngeal
bacteria in the gut
Body site of origin of the altered bacteria was investigated to
shed light on the mechanism driving observed associations. Data
from the human microbiome project (HMP) was used as a refer-
ence to determine body site preferences of bacterial families (see
online supplementary methods and supplementary table S6). It
is worth noting that individual species within each family may
be commensals at different and multiple sites. Here we simply
aimed to determine overall if families were more frequently
identiﬁed at particular body sites.
Within the ﬁve families found to associate negatively with PPI
use in TwinsUK, four were more common in the gut, with two
also being found in abundance in the mouth/throat. The excep-
tion was Cyanobacteria, which was not biased towards any site in
the HMP data. All 10 families positively associated with PPI use
(including four replicated in the interventional study) displayed
site preference. The six strongest, most signiﬁcantly associated
families were enriched in the mouth/throat with one also in abun-
dance in the skin/nose, one was only enriched at the skin/nose
sites, and two were most commonly found at vaginal sites. The
only family most common to the gut and with increased abun-
dance with PPI use was Burkholderiaceae. Overall, families with
signiﬁcantly reduced abundance with PPI use were more often
found in the gut in the HMP data; while families with signiﬁ-
cantly higher abundance with PPI use were more often found in
the mouth/throat, skin/nose or vaginal sites (likely a result of the
large number of Lactobacillaceae commensals found here).23
To determine if this trend applied to all families, including
those not signiﬁcantly associated with PPI use, coefﬁcients of
association of each family with each site in the HMP data were
correlated against families’ associations with PPI use in the
TwinsUK data. There was a non-signiﬁcant negative correlation
between the association with PPI use and with the gut (ρ=
−0.23, p=0.07), and a non-signiﬁcant positive correlation with
vaginal coefﬁcients (ρ=0.2, p=0.12). However, signiﬁcant posi-
tive correlations were observed between the association with PPI
use and the association with the mouth/throat (ρ=0.38,
p=0.0019) and the skin/nose (ρ=0.36, p=0.003) sites.
DISCUSSION
We have proﬁled the effects of PPI use on the gut microbiome
in by far the largest study to date, and considered a number of
Figure 1 Distributions of covariates included for analysis, compared between proton pump inhibitor (PPI) users and non-users. Wilcoxon rank sum
tests were carried out to compare the distribution of covariates in the modelling analysis. All variables were on a different scale so were centred and
scaled before plotting. PPI users were older, frailer, had higher body mass index (BMI) and lower scores on the high alcohol food frequency
questionnaire (FFQ) principle component (PC). Signiﬁcant differences are indicated where ***p<0.001 and **p<0.01.
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possible confounders including host genetics. We have demon-
strated that PPI use is associated with an altered composition of
the gut microbiota, and a moderately lower diversity. In all three
analyses, the large observational study, between discordant
twins, and the interventional replication, PPI use was associated
with increases in the Lactobacillales order, and in particular the
family Streptococcaceae. Further, we show these effects could
result from downward movement of upper tract commensals.
We observed a signiﬁcant reduction in microbial diversity
with PPIs. However, it was a small difference and became non-
signiﬁcant after adjusting for covariates. This may be due to con-
founding effects and/or reduced power of the smaller sample.
Variables we found to associate with PPIs, such as BMI, frailty,
and antibiotic use, are also known to reduce diversity.24 26 40
Therefore, it is likely that these factors are partly responsible for
the observed lower diversity in PPI users; such confounders
were also not accounted for in previous observations of
decreased diversity with PPI use.32 This is further supported by
a number of studies where no major changes in diversity have
been observed.28 30
Figure 2 Comparison of α diversity in proton pump inhibitor (PPI) users and non-users, and in individuals with and without GI indications. Four
metrics of α diversity were calculated on rareﬁed samples and one-tailed Wilcoxon rank sum tests carried out to test for signiﬁcantly lower diversity
with PPI use, or with GI indication. Signiﬁcantly lower diversity was observed for all metrics in PPI users versus non-users (*); no difference was
found splitting by GI indication (NS).
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There was a clear association between the composition of
the microbiome and PPI utilisation. Collapsing by taxonomic
assignment revealed the lineage speciﬁcity of these associa-
tions, in particular to those containing Streptococcaceae and
other Lactobacilli. A number of these associations have been
identiﬁed in smaller studies. For example, 8 weeks of PPI use
was found to increase the abundance of Actinomycetales and
Lactobacillales in the oesophagus of 34 patients suffering
from heartburn.29 An increase in Streptococcus was also
observed with PPI use in a case–control study of 116 chil-
dren,30 and previous analyses of the intervention study data
utilised within this study also identiﬁed similar increases in
Streptococcaceae and Micrococcaceae.31 These studies also
identiﬁed changes not present in our study, for example,
increases in Gemellales, Enterococacceae, and
Staphylocacceae.29 31
We found families with higher abundance with PPI use to be
frequent commensals of the oral, throat, nasal, and skin commu-
nities. We hypothesise that under normal circumstances gastric
acid acts as a barrier to progression down the GI tract for pha-
ryngeal commensals and environmental bacteria, which are not
well adapted to low pH. Treatment with PPIs removes this
barrier allowing colonisation by these bacteria further along the
GI tract, eventually translating to the detected increased abun-
dance in faecal samples. As observations are based on relative
abundances, the observed lower abundance of gut commensals
likely reﬂects the increase in other taxa, rather than a reduction
in absolute levels.
PPIs may also act on speciﬁc bacterial taxa directly. Previous
evidence suggests that they may have antimicrobial action
against Helicobacter pylori.41 42 Also, at least one Streptococcus
species is known to have P-type ATPase transporters belonging
Figure 3 Summary of taxonomic associations with proton pump inhibitor (PPI) use. Shown are all collapsed groups used in taxonomic association
analyses that had complete taxonomic assignment (not including collapsed species). Connecting lines highlight the taxonomic relationships between
groups (not considering genetic relatedness). Taxa signiﬁcantly associated with PPI use are highlighted with circles, larger circles representing a
larger absolute coefﬁcient of association. Association analyses were carried out at each taxonomic level independently. Taxa at higher abundance
with PPI use are shown in blue and at lower abundance in red. Lines connecting taxa of similar association are also coloured and weighted by the
average coefﬁcient between the taxa. Names are shown for signiﬁcant results only. Those in bold retained signiﬁcance between 70 discordant
monozygotic (MZ) twins, and underlined taxa replicated in analysis of interventional study data.
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to the same enzyme family as the human H+/K+ ATPase tar-
geted by PPIs.43 Bacterial targets for direct PPI interactions
could drive species-speciﬁc compositional changes.
There are limitations to the study. The TwinsUK data are
observational, although our key ﬁndings were conﬁrmed
between twin pairs and replicated in data from a small prospect-
ive controlled trial. PPI use and GI indication were self-reported
and over a wide timespan from faecal sampling. However, mis-
classiﬁcation of exposures should only serve to reduce the
strength of observed associations. We have also omitted duration
of PPI use as accurate data were not available, which should be
considered in future investigations as it may inﬂuence the
strength of microbiome associations. However, the lack of dur-
ation data would tend to dilute our associations as short and
long-term users are classiﬁed together. Similarly, we did not con-
sider the effects of withdrawal of PPI treatment, which may be
important given that dysbioses resulting from antibiotic use can
have long lasting effects.40
Antibiotic use was not scored for all individuals within this
study; we have also not considered the effects of particular
classes of antibiotics, dosage and duration of courses, or anti-
biotic use before the previous month. However, the robustness
of our observations within the subset of individuals who had
not used antibiotics shows that they are independent of the
effects of recent antibiotic exposure. This study was also limited
to faecal sampling. While the observations in the gut are robust,
they offer no insight into the distribution of these bacteria along
the GI tract. Sampling of multiple sites combined with culture
experiments would determine the distribution of living bacteria,
and the inﬂuence of upper tract community composition on
subsequent changes in the gut. In vitro studies will also be
required to elucidate whether our observations are driven by pH
changes, direct drug interactions, or a combination of both.
This will be particularly important to determine if these effects
occur with other classes of acid-suppressing medication.
The associations reported here are of clinical importance. C
difﬁcile affects nearly half a million people in the USA annually,44
and is known to capitalise on alterations to the normal gut micro-
biota.27 The increased risk of enteric infection with PPI use may
similarly be mediated through changes to the GI microbiome. It
has been shown that a high abundance of Streptococcus in the
gut predisposes mice to C difﬁcile colonisation, while
Lachnospiraceae are protective.45 On this basis, we observed
taxonomic changes that would be expected to promote C difﬁcile
infection. Further investigations into the microbiome-mediated
determinants of C difﬁcile infection will be important to under-
stand how to mitigate the risk associated with PPI use.
A further consequence for consideration is the potential for
the GI tract to become a reservoir for potential pathogens at
alternate body sites. A signiﬁcant increased risk of
community-acquired pneumonia has been observed with PPIs
(relative risk 1.98 for users vs ex-users),18 and has been
observed speciﬁcally for Streptococcus derived pneumonia.46
There is speculative evidence of bacterial exchanges between the
gastric and lung ﬂuids,30 47 and depletion of the gut microbiota
reduces immune mediated resilience to pneumococcal pneumo-
nia in mice.48 PPI use has also been shown to increase the risk
of spontaneous bacterial peritonitis and overall bacterial infec-
tion in patients with cirrhosis and ascites,19 suggesting PPI use
may pose a higher risk to individuals already susceptible to
infection and other complications; for example, the elderly and
the more frail or more obese individuals, whom our study indi-
cates are more likely to be prescribed PPIs.
The described associations between PPI use and the gut
microbiome warrant further research to better understand the
driving mechanisms and their consequences, and are a further
reason to reduce unnecessary prescribing.
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